 <h1>Alirocumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to alirocumab: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, alirocumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking alirocumab:</p><p>
<i>More common</i>
</p><ul>
<li>Chest pain</li>
<li>difficulty with breathing or swallowing</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives, itching, skin rash</li>
<li>irritation</li>
<li>hoarseness</li>
<li>joint pain, stiffness, or swelling</li>
<li>nausea</li>
<li>reddening of the skin, especially around the ears</li>
<li>swelling of eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough producing mucus</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of alirocumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>loss of appetite</li>
<li>muscle aches, cramps, stiffness, or pains</li>
<li>shivering</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>bone pain</li>
<li>bruise</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with moving</li>
<li>frequent urge to urinate</li>
<li>lower back or side pain</li>
<li>muscle spasms</li>
<li>pain or tenderness around the eyes and cheekbones</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alirocumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included nasopharyngitis, injection site reactions, and influenza.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reaction, nummular eczema, hypersensitivity vasculitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (11.3%)</p>
<p><b>Common</b> (1% to 10%): Influenza, bronchitis, sinusitis, cough<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver enzymes<sup>[Ref]</sup></p><p>During clinical trials, 2.5% of patients treated with this drug reported abnormal liver enzymes (placebo=1.8%); treatment discontinuation occurred in 0.4% and 0.2% of patients receiving this drug and placebo, respectively.  Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with this drug (placebo=1.4%).<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Development of antidrug antibody (ADA), neutralizing antibodies (NAb)</p>
<p><b>Postmarketing reports</b>: Flu-like illness<sup>[Ref]</sup></p><h3>Local</h3><p>Patients who developed ADA (antidrug antibody) had a higher incidence of injection site reactions compared with patients who did not develop ADA (10.2% vs 5.9%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site reaction (erythema, redness, itching, swelling, pain, tenderness)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, muscle spasm, contusion, musculoskeletal pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Neurocognitive events, confusion or memory impairment<sup>[Ref]</sup></p><h3>Metabolic</h3><p>During clinical trials with both every 2 week or every 4 week dosing, reports of 2 consecutive calculated LDL-C values less than 25 mg/dL, and less than 15 mg/dL were reported in 914 and 335 patients, respectively.  Low LDL-C values were observed more frequently in patients treated with 150 mg every 2 weeks or 400 mg every 4 weeks.  Changes to background lipid therapy was not made and adverse consequences were not identified, but the long-term effects of very low levels of LDL-C are not known.</p><p><b>Frequency not reported</b>: Low LDL-C values</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Praluent Pen (alirocumab)." sanofi-aventis, Bridgewater, NJ. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Praluent vs Repatha: What's the difference?</li>
<li>Does it lower triglycerides?</li>
<li>How does Praluent work?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about alirocumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>129 Reviews</li>
<li>Drug class: PCSK9 inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alirocumab Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Praluent</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cardiovascular Risk Reduction</li>
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Heterozygous</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to alirocumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included nasopharyngitis, injection site reactions, and influenza.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity reaction, nummular eczema, hypersensitivity vasculitis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (11.3%)</p><p><b>Common</b> (1% to 10%): Influenza, bronchitis, sinusitis, cough<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver enzymes<sup>[Ref]</sup></p><p>During clinical trials, 2.5% of patients treated with this drug reported abnormal liver enzymes (placebo=1.8%); treatment discontinuation occurred in 0.4% and 0.2% of patients receiving this drug and placebo, respectively.  Increases in serum transaminases to greater than 3 times the upper limit of normal occurred in 1.7% of patients treated with this drug (placebo=1.4%).<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Development of antidrug antibody (ADA), neutralizing antibodies (NAb)</p><p><b>Postmarketing reports</b>: Flu-like illness<sup>[Ref]</sup></p><h3>Local</h3><p>Patients who developed ADA (antidrug antibody) had a higher incidence of injection site reactions compared with patients who did not develop ADA (10.2% vs 5.9%).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site reaction (erythema, redness, itching, swelling, pain, tenderness)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, muscle spasm, contusion, musculoskeletal pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Neurocognitive events, confusion or memory impairment<sup>[Ref]</sup></p><h3>Metabolic</h3><p>During clinical trials with both every 2 week or every 4 week dosing, reports of 2 consecutive calculated LDL-C values less than 25 mg/dL, and less than 15 mg/dL were reported in 914 and 335 patients, respectively.  Low LDL-C values were observed more frequently in patients treated with 150 mg every 2 weeks or 400 mg every 4 weeks.  Changes to background lipid therapy was not made and adverse consequences were not identified, but the long-term effects of very low levels of LDL-C are not known.</p><p><b>Frequency not reported</b>: Low LDL-C values</p><p id="ref_1">1. "Product Information. Praluent Pen (alirocumab)." sanofi-aventis, Bridgewater, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Praluent vs Repatha: What's the difference?</li>
<li>Does it lower triglycerides?</li>
<li>How does Praluent work?</li>
</ul><h2>More about alirocumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>129 Reviews</li>
<li>Drug class: PCSK9 inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Alirocumab Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cardiovascular Risk Reduction</li>
<li>High Cholesterol</li>
<li>High Cholesterol, Familial Heterozygous</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>